Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation

[1]  A. Briones,et al.  Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity , 2014, Journal of hypertension.

[2]  C. Jenkinson,et al.  The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus , 2014, Acta Diabetologica.

[3]  Kassem M. Makki,et al.  Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines , 2013, ISRN inflammation.

[4]  F. Zannad,et al.  A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats , 2013, PloS one.

[5]  G. Maurer,et al.  Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature , 2013, Journal of molecular and cellular cardiology.

[6]  L. Groop,et al.  Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.

[7]  J. Wojta,et al.  Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue , 2013, International Journal of Obesity.

[8]  F. Ruschitzka,et al.  Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity , 2013, European heart journal.

[9]  R. D. de Boer,et al.  Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[10]  G. Adler,et al.  The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans , 2013, Current Hypertension Reports.

[11]  N. Sattar,et al.  Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes? , 2012, PloS one.

[12]  R. Touyz,et al.  Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways: Implications in Diabetes Mellitus–Associated Obesity and Vascular Dysfunction , 2012, Hypertension.

[13]  T. Economopoulos,et al.  Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction , 2011, Cardiovascular diabetology.

[14]  M. Zennaro,et al.  Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. , 2010, Endocrinology.

[15]  Fabio Salamanca-Gómez,et al.  Roberto Martínez Martínez , 2011 .

[16]  Ashley M. Miller,et al.  Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice , 2010, Circulation research.

[17]  J. Klein,et al.  The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. , 2010, The Journal of endocrinology.

[18]  O. Muller,et al.  Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. , 2008, Journal of the American College of Cardiology.

[19]  D. Rizzoni,et al.  Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  Dirk E. Smith,et al.  The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. , 2008, Cytokine.

[21]  A. Krug,et al.  Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor? , 2008, Hypertension.

[22]  G. Adler,et al.  Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-&ggr;, and Proinflammatory Adipokines , 2008, Circulation.

[23]  Maria-Christina Zennaro,et al.  Pivotal role of the mineralocorticoid receptor in corticosteroid‐induced adipogenesis , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  R. Schmieder,et al.  Renin-angiotensin system and cardiovascular risk , 2007, The Lancet.

[25]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[26]  P. Fesler,et al.  Relative glomerular hyperfiltration in primary aldosteronism. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  V. Cachofeiro,et al.  In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess , 1998, Molecular and Cellular Biochemistry.

[28]  Arya M. Sharma,et al.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? , 2003, The international journal of biochemistry & cell biology.

[29]  M. Hayakawa,et al.  Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. , 2001, Biochemical and biophysical research communications.

[30]  H. Iwahana,et al.  The cloning and nucleotide sequence of human ST2L cDNA. , 2000, Genomics.

[31]  L. Ruilope,et al.  Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats , 1998, Journal of hypertension.

[32]  M. Baker,et al.  Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. , 1993, Endocrinology.